85 related articles for article (PubMed ID: 21366513)
21. Dexlansoprazole - a new-generation proton pump inhibitor.
Skrzydło-Radomańska B; Radwan P
Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
[TBL] [Abstract][Full Text] [Related]
22. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Wittbrodt ET; Baum C; Peura DA
Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines.
Novotna A; Srovnalova A; Svecarova M; Korhonova M; Bartonkova I; Dvorak Z
PLoS One; 2014; 9(6):e98711. PubMed ID: 24887303
[TBL] [Abstract][Full Text] [Related]
24. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
25. Guidelines for the diagnosis and management of gastroesophageal reflux disease.
Katz PO; Gerson LB; Vela MF
Am J Gastroenterol; 2013 Mar; 108(3):308-28; quiz 329. PubMed ID: 23419381
[No Abstract] [Full Text] [Related]
26. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
27. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
[TBL] [Abstract][Full Text] [Related]
30. The Usefulness of the Measurement of Esophagogastric Junction Distensibility by EndoFLIP in the Diagnosis of Gastroesophageal Reflux Disease.
Lee JM; Yoo IK; Kim E; Hong SP; Cho JY
Gut Liver; 2021 Jul; 15(4):546-552. PubMed ID: 33115968
[TBL] [Abstract][Full Text] [Related]
31. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.
Oshima T; Miwa H
J Neurogastroenterol Motil; 2018 Jul; 24(3):334-344. PubMed ID: 29739175
[TBL] [Abstract][Full Text] [Related]
32. The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.
Gąsiorowska A
Prz Gastroenterol; 2017; 12(4):244-249. PubMed ID: 29358992
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.
Kung YM; Hsu WH; Wu MC; Wang JW; Liu CJ; Su YC; Kuo CH; Kuo FC; Wu DC; Wang YK
Dig Dis Sci; 2017 Dec; 62(12):3298-3316. PubMed ID: 29110162
[TBL] [Abstract][Full Text] [Related]
34. Impact of Gastric
Sun LN; Cao Y; Li YQ; Fang YQ; Zhang HW; Wang MF; Xie LJ; Chen J; Yang ZC; Bian ML; Li H; Zhang PP; Wei JF; Meng L; Zhang XH; Zhao P; Wang YQ
Front Pharmacol; 2017; 8():670. PubMed ID: 29018343
[No Abstract] [Full Text] [Related]
35. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Fass R; Frazier R
Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
Mermelstein J; Mermelstein AC; Chait MM
Clin Exp Gastroenterol; 2016; 9():163-72. PubMed ID: 27471402
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
